635305-32-7Relevant academic research and scientific papers
Cu-Catalyzed cross-coupling reactions of epoxides with organoboron compounds
Lu, Xiao-Yu,Yang, Chu-Ting,Liu, Jing-Hui,Zhang, Zheng-Qi,Lu, Xi,Lou, Xin,Xiao, Bin,Fu, Yao
supporting information, p. 2388 - 2391 (2015/02/05)
A copper-catalyzed cross-coupling reaction of epoxides with arylboronates is described. This reaction is not limited to aromatic epoxides, because aliphatic epoxides are also suitable substrates. In addition, N-sulfonyl aziridines can be successfully converted into the products. This reaction provides convenient access to β-phenethyl alcohols, which are valuable synthetic intermediates.
Nickel-catalysed carboxylation of organoboronates
Makida, Yusuke,Marelli, Enrico,Slawin, Alexandra M. Z.,Nolan, Steven P.
supporting information, p. 8010 - 8013 (2014/07/08)
A nickel/N-heterocyclic carbene (NHC) catalysed carboxylation of aryl-, heteroaryl- and alkenylboronates, affording the corresponding carboxylic acids, has been developed. This transformation proceeds under one atmosphere of CO 2 with a broad range of substrates and exhibits good functional group compatibility. the Partner Organisations 2014.
C-2 arylation of piperidines through directed transition-metal-catalyzed sp3 C-H activation
Prokopcova, Hana,Bergman, Sheba D.,Aelvoet, Karel,Smout, Veerle,Herrebout, Wouter,Van Der Veken, Benjamin,Meerpoel, Lieven,Maes, Bert U. W.
supporting information; experimental part, p. 13063 - 13067 (2011/02/21)
All you need is an open vial! The direct α arylation of cyclic alkylamines (see scheme) requires an open vial, as the hydrogen atom involved in the C(sp3)-H-activation process is ultimately released as hydrogen gas. Reports on the formation of hydrogen gas in direct transition-metal- catalyzed functionalizations are still rare. Open-vial reactions proved crucial to this direct arylation procedure as, upon sealing, catalyst deactivation occurs.
PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF
-
Page 30, (2008/06/13)
Use of compounds to inhibit hormone-sensitive lipase, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, method of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitve lipase and may be useful in the treatment and/or prevention of a range of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.
